Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Jay Moorin. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Jay Moorin har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:URGN / UroGen Pharma Ltd. | 10% Owner | 1.242.031 |
US:EGRX / Eagle Pharmaceuticals, Inc. | 10% Owner | 149.107 |
US:AGRX / Agile Therapeutics, Inc. | 10% Owner | 5.062.363 |
US:ARNI / Arno Therapeutics, Inc. | Director | 88.648 |
US:IMDZ / Immune Design Corp. | 10% Owner | 1.983.858 |
US:PGSI / Pegasi Energy Resources Corp. | Director | 694.444 |
US:NVDL / GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF | 10% Owner | 17.120.360 |
US:AVNR / Avanir Pharmaceuticals Inc | 10% Owner | 7.820.470 |
US:PTN / Palatin Technologies, Inc. | 10% Owner | 5.803.972 |
US:THLD / Threshold Pharmaceuticals, Inc. | 10% Owner | 3.301.565 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Jay Moorin. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ARNI / Arno Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ARNI / Arno Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ARNI / Arno Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ARNI / Arno Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EGRX / Eagle Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ARNI / Arno Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EGRX / Eagle Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ARNI / Arno Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NVDL / GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ARNI / Arno Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NVDL / GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ARNI / Arno Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb URGN / UroGen Pharma Ltd. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ARNI / Arno Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg URGN / UroGen Pharma Ltd. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ARNI / Arno Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Jay Moorin som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2017-11-29 |
|
4 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
S - Sale | -177.807 | 1.242.031 | -12,52 | 40,51 | -7.202.962 | 50.314.676 | |
2017-11-29 |
|
4 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
S - Sale | -31.491 | 1.419.838 | -2,17 | 41,12 | -1.294.910 | 58.383.739 | |
2017-07-20 | 3 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
2.902.658 | ||||||||
2017-07-20 | 3 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
2.902.658 | ||||||||
2017-07-20 | 3 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
2.902.658 | ||||||||
2017-07-20 | 3 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
2.902.658 | ||||||||
2017-07-20 | 3 | URGN |
UroGen Pharma Ltd.
Ordinary Shares, par value NIS 0.01 per share |
2.902.658 | ||||||||
2017-05-15 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
J - Other | 149.107 | 149.107 | |||||
2017-05-15 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
J - Other | 149.107 | 162.661 | 1.100,10 | ||||
2017-05-15 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
J - Other | -3.584.087 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -20.000 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -10.000 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -9.360 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -3.120 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -2.340 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -2.340 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -2.340 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -2.340 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -2.340 | 0 | -100,00 | ||||
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -2.961 | 6.777 | -30,41 | 89,09 | -263.795 | 603.763 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -51.219 | 9.738 | -84,02 | 88,34 | -4.524.686 | 860.255 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 20.000 | 60.957 | 48,83 | 59,31 | 1.186.200 | 3.615.360 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 10.000 | 40.957 | 32,30 | 46,09 | 460.900 | 1.887.708 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 9.360 | 30.957 | 43,34 | 12,67 | 118.591 | 392.225 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 3.120 | 21.597 | 16,89 | 4,42 | 13.790 | 95.459 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 2.340 | 18.477 | 14,50 | 8,78 | 20.545 | 162.228 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 2.340 | 10.840.560 | 0,02 | 8,78 | 20.545 | 95.180.117 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 2.340 | 18.477 | 14,50 | 8,78 | 20.545 | 162.228 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 2.340 | 11.457 | 25,67 | 4,04 | 9.454 | 46.286 | |
2017-04-27 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
M - Exercise | 2.340 | 9.117 | 34,53 | 0,90 | 2.106 | 8.205 | |
2017-04-03 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -61.420 | 3.584.087 | -1,68 | 83,13 | -5.105.845 | 297.945.152 | |
2017-04-03 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -23.689 | 3.645.507 | -0,65 | 83,02 | -1.966.661 | 302.649.991 | |
2017-04-03 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -6.223 | 3.669.196 | -0,17 | 83,00 | -516.509 | 304.543.268 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -1.600 | 23.274 | -6,43 | 83,01 | -132.816 | 1.931.975 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -500 | 6.777 | -6,87 | 83,01 | -41.505 | 562.559 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -58.755 | 3.675.419 | -1,57 | 83,01 | -4.877.253 | 305.096.531 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -6.182 | 3.734.174 | -0,17 | 83,02 | -513.230 | 310.011.125 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -1.300 | 24.874 | -4,97 | 83,00 | -107.900 | 2.064.542 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -400 | 7.277 | -5,21 | 83,00 | -33.200 | 603.991 | |
2017-03-29 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -37.731 | 3.740.356 | -1,00 | 83,00 | -3.131.673 | 310.449.548 | |
2017-03-23 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -700 | 3.778.087 | -0,02 | 83,01 | -58.107 | 313.619.002 | |
2017-03-23 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -500 | 3.778.787 | -0,01 | 83,10 | -41.550 | 314.017.200 | |
2017-03-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -51.883 | 3.779.287 | -1,35 | 82,10 | -4.259.594 | 310.279.463 | |
2017-03-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0,001 par value |
S - Sale | -38.997 | 3.831.170 | -1,01 | 82,01 | -3.198.144 | 314.194.252 | |
2017-03-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -9.120 | 3.870.167 | -0,24 | 82,08 | -748.570 | 317.663.307 | |
2017-01-06 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -65.114 | 3.879.287 | -1,65 | 85,16 | -5.545.108 | 330.360.081 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -15.551 | 3.944.401 | -0,39 | 85,00 | -1.321.835 | 335.274.085 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -1.300 | 26.174 | -4,73 | 85,00 | -110.500 | 2.224.790 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -300 | 7.677 | -3,76 | 85,00 | -25.500 | 652.545 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -1.700 | 3.959.952 | -0,04 | 87,05 | -147.985 | 344.713.822 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -100 | 3.961.652 | 0,00 | 86,06 | -8.606 | 340.939.771 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -167 | 3.961.752 | 0,00 | 86,00 | -14.362 | 340.710.672 | |
2016-11-14 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -15.368 | 3.961.919 | -0,39 | 85,10 | -1.307.817 | 337.159.307 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -102.919 | 3.977.287 | -2,52 | 80,09 | -8.242.783 | 318.540.916 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -19.581 | 4.080.206 | -0,48 | 79,24 | -1.551.598 | 323.315.523 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -4.200 | 4.099.787 | -0,10 | 78,23 | -328.566 | 320.726.337 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -9.030 | 4.103.987 | -0,22 | 77,13 | -696.484 | 316.540.517 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -11.690 | 4.113.017 | -0,28 | 76,49 | -894.168 | 314.604.670 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -1.380 | 4.124.707 | -0,03 | 75,70 | -104.466 | 312.240.320 | |
2016-11-09 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -5.030 | 4.126.087 | -0,12 | 75,39 | -379.212 | 311.065.699 | |
2016-11-04 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -46.170 | 4.181.446 | -1,09 | 75,00 | -3.462.750 | 313.608.450 | |
2016-11-04 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -2.100 | 27.474 | -7,10 | 70,00 | -147.000 | 1.923.180 | |
2016-11-04 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -800 | 7.977 | -9,11 | 70,00 | -56.000 | 558.390 | |
2016-11-04 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -50.329 | 4.177.287 | -1,19 | 70,41 | -3.543.665 | 294.122.778 | |
2016-11-04 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -146.371 | 4.227.616 | -3,35 | 70,00 | -10.245.970 | 295.933.120 | |
2016-10-04 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -22.100 | 4.373.987 | -0,50 | 70,06 | -1.548.326 | 306.441.529 | |
2016-09-30 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -77.900 | 4.396.087 | -1,74 | 70,04 | -5.456.116 | 307.901.933 | |
2016-09-23 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -654 | 29.574 | -2,16 | 66,17 | -43.275 | 1.956.912 | |
2016-09-23 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -194 | 8.777 | -2,16 | 66,17 | -12.837 | 580.774 | |
2016-09-23 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -1.798 | 4.473.987 | -0,04 | 67,24 | -120.898 | 300.830.886 | |
2016-09-23 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -97.149 | 4.475.785 | -2,12 | 66,15 | -6.426.406 | 296.073.178 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -224 | 30.228 | -0,74 | 62,33 | -13.962 | 1.884.111 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -66 | 8.971 | -0,73 | 62,33 | -4.114 | 559.162 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -33.796 | 4.572.934 | -0,73 | 62,33 | -2.106.505 | 285.030.976 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -75 | 30.452 | -0,25 | 62,26 | -4.670 | 1.895.942 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -22 | 9.037 | -0,24 | 62,26 | -1.370 | 562.644 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -11.345 | 4.606.730 | -0,25 | 62,26 | -706.340 | 286.815.010 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -166 | 30.527 | -0,54 | 62,83 | -10.430 | 1.918.011 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -49 | 9.059 | -0,54 | 62,83 | -3.079 | 569.177 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -12.224 | 4.618.075 | -0,26 | 63,25 | -773.168 | 292.093.244 | |
2016-09-08 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -12.958 | 4.630.299 | -0,28 | 62,45 | -809.227 | 289.162.173 | |
2016-08-25 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -76 | 30.693 | -0,25 | 62,78 | -4.771 | 1.926.907 | |
2016-08-25 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -23 | 9.108 | -0,25 | 62,78 | -1.444 | 571.800 | |
2016-08-25 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -11.506 | 4.643.257 | -0,25 | 62,78 | -722.347 | 291.503.674 | |
2016-08-25 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -113 | 30.769 | -0,37 | 63,12 | -7.133 | 1.942.139 | |
2016-08-25 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -34 | 9.131 | -0,37 | 63,12 | -2.146 | 576.349 | |
2016-08-25 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -17.118 | 4.654.763 | -0,37 | 63,14 | -1.080.831 | 293.901.736 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -96 | 30.882 | -0,31 | 61,00 | -5.856 | 1.883.802 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -29 | 5.387 | -0,54 | 61,00 | -1.769 | 328.607 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -9.848 | 4.671.779 | -0,21 | 61,19 | -602.599 | 285.866.157 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -4.723 | 4.681.627 | -0,10 | 60,85 | -287.395 | 284.877.003 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -394 | 30.978 | -1,26 | 60,78 | -23.947 | 1.882.843 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -117 | 5.416 | -2,11 | 60,78 | -7.111 | 329.184 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -31.599 | 4.686.350 | -0,67 | 62,21 | -1.965.774 | 291.537.834 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -11.770 | 4.717.949 | -0,25 | 61,65 | -725.620 | 290.861.556 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -16.270 | 4.729.719 | -0,34 | 60,66 | -986.938 | 286.904.755 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -163 | 31.372 | -0,52 | 60,70 | -9.894 | 1.904.280 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0,001 par value |
S - Sale | -49 | 5.533 | -0,88 | 60,70 | -2.974 | 335.853 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0.001 par value |
S - Sale | -8.070 | 4.745.989 | -0,17 | 61,31 | -494.772 | 290.976.586 | |
2016-08-17 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -16.667 | 4.754.059 | -0,35 | 60,51 | -1.008.520 | 287.668.110 | |
2016-06-30 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0,001 par value |
J - Other | -9.903 | 5.582 | -63,95 | ||||
2016-05-24 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0,001 par value |
J - Other | -9.360 | 9.360 | -50,00 | ||||
2016-05-24 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -4.770.828 | 4.770.828 | -50,00 | ||||
2016-05-16 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock $0,001 par value |
S - Sale | -13.980 | 41.081 | -25,39 | 40,92 | -572.062 | 1.681.035 | |
2016-05-16 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -4.000 | 55.061 | -6,77 | 40,00 | -160.000 | 2.202.440 | |
2016-01-29 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 393.700 | 5.062.363 | 8,43 | 6,35 | 2.499.995 | 32.146.005 | |
2016-01-14 |
|
4 | ARNI |
Arno Therapeutics, Inc
Stock Option (right to buy) |
A - Award | 88.648 | 88.648 | |||||
2016-01-14 | 3 | ARNI |
Arno Therapeutics, Inc
Common Stock |
1.285.716 | ||||||||
2016-01-14 | 3 | ARNI |
Arno Therapeutics, Inc
Common Stock |
1.285.716 | ||||||||
2016-01-05 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2015-07-02 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2.970 | 59.061 | -4,79 | ||||
2015-05-13 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -155.000 | 1.983.858 | -7,25 | 21,50 | -3.332.500 | 42.652.947 | |
2015-05-13 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -22.607 | 2.138.858 | -1,05 | 22,26 | -503.232 | 47.610.979 | |
2015-05-07 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -9.903 | 62.031 | -13,77 | ||||
2015-04-24 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -25.000 | 2.161.465 | -1,14 | 26,64 | -666.000 | 57.581.428 | |
2015-04-24 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -22.643 | 2.186.465 | -1,02 | 27,35 | -619.286 | 59.799.818 | |
2015-04-24 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -10.000 | 2.209.108 | -0,45 | 26,64 | -266.400 | 58.850.637 | |
2015-04-24 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -25.249 | 2.219.108 | -1,12 | 26,56 | -670.613 | 58.939.508 | |
2015-04-22 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10.000 | 10.000 | |||||
2015-04-21 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -14.167 | 2.244.357 | -0,63 | 26,35 | -373.300 | 59.138.807 | |
2015-04-21 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -12.792 | 2.258.524 | -0,56 | 26,44 | -338.220 | 59.715.375 | |
2015-04-21 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -18.861 | 2.271.316 | -0,82 | 26,67 | -503.023 | 60.575.998 | |
2015-04-16 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -100 | 2.290.177 | 0,00 | 26,75 | -2.675 | 61.262.235 | |
2015-04-16 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -100 | 2.290.277 | 0,00 | 29,17 | -2.917 | 66.807.380 | |
2015-04-16 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -39.900 | 2.290.377 | -1,71 | 28,57 | -1.139.943 | 65.436.071 | |
2015-04-16 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -13.814 | 2.330.277 | -0,59 | 27,26 | -376.570 | 63.523.351 | |
2015-04-08 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -3.600 | 2.344.091 | -0,15 | 26,55 | -95.580 | 62.235.616 | |
2015-04-08 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -3.895 | 2.347.691 | -0,17 | 26,88 | -104.698 | 63.105.934 | |
2015-04-02 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -8.035 | 2.351.586 | -0,34 | 27,07 | -217.507 | 63.657.433 | |
2015-04-02 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -39.819 | 2.359.621 | -1,66 | 26,55 | -1.057.194 | 62.647.938 | |
2015-04-02 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -14.600 | 2.399.440 | -0,60 | 25,51 | -372.446 | 61.209.714 | |
2015-03-26 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -4.956 | 2.414.040 | -0,20 | 27,56 | -136.587 | 66.530.942 | |
2015-03-26 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -13.200 | 2.418.996 | -0,54 | 27,67 | -365.244 | 66.933.619 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -5.000 | 2.432.196 | -0,21 | 27,78 | -138.900 | 67.566.405 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -84 | 2.437.196 | 0,00 | 28,15 | -2.365 | 68.607.067 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -400 | 2.437.280 | -0,02 | 28,13 | -11.252 | 68.560.686 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -200 | 2.437.680 | -0,01 | 28,04 | -5.608 | 68.352.547 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -8.780 | 2.437.880 | -0,36 | 27,19 | -238.749 | 66.291.808 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -200 | 2.446.660 | -0,01 | 28,07 | -5.614 | 68.677.746 | |
2015-03-23 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -29.800 | 2.446.860 | -1,20 | 27,55 | -820.990 | 67.410.993 | |
2015-03-18 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -100 | 2.476.660 | 0,00 | 27,02 | -2.702 | 66.919.353 | |
2015-03-18 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -500 | 2.476.760 | -0,02 | 26,99 | -13.495 | 66.847.752 | |
2015-03-18 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -100 | 2.477.260 | 0,00 | 27,04 | -2.704 | 66.985.110 | |
2015-03-18 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -19.300 | 2.477.360 | -0,77 | 26,56 | -512.608 | 65.798.682 | |
2015-03-18 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -20.000 | 2.496.660 | -0,79 | 25,94 | -518.800 | 64.763.360 | |
2015-03-18 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -10.309 | 2.516.660 | -0,41 | 25,43 | -262.158 | 63.998.664 | |
2015-03-18 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Option (right to buy) |
A - Award | 5.000 | 5.000 | |||||
2015-03-12 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -94.199 | 2.526.969 | -3,59 | 24,94 | -2.349.323 | 63.022.607 | |
2015-03-12 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -29.000 | 2.621.168 | -1,09 | 25,02 | -725.580 | 65.581.623 | |
2015-03-12 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -6.143 | 2.650.168 | -0,23 | 24,65 | -151.425 | 65.326.641 | |
2015-03-09 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -32.300 | 2.656.311 | -1,20 | 25,61 | -827.203 | 68.028.125 | |
2015-03-09 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -100 | 2.688.611 | 0,00 | 25,02 | -2.502 | 67.269.047 | |
2015-03-09 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -1.046 | 2.688.711 | -0,04 | 25,00 | -26.150 | 67.217.775 | |
2015-03-09 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -6.000 | 2.689.757 | -0,22 | 24,65 | -147.900 | 66.302.510 | |
2015-01-23 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 811.966 | 4.668.663 | 21,05 | 5,85 | 4.750.001 | 27.311.679 | |
2015-01-20 |
|
4 | PGSI |
Pegasi Energy Resources Corporation.
Warrants |
P - Purchase | 694.444 | 694.444 | |||||
2015-01-20 |
|
4 | PGSI |
Pegasi Energy Resources Corporation.
Convertible Note |
P - Purchase | 250.000 | 250.000 | 250.000,00 | 62.500.000.000 | 62.500.000.000 | ||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock |
C - Conversion | -305.810 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock |
X - Other | 305.810 | 305.810 | |||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock Warrant (right to buy) |
X - Other | -305.810 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock |
C - Conversion | -611.620 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series B Preferred Stock |
C - Conversion | -1.595.530 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
P - Purchase | 391.131 | 2.695.757 | 16,97 | 12,00 | 4.693.572 | 32.349.084 | |
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
S - Sale | -208.334 | 2.304.626 | -8,29 | 12,00 | -2.500.008 | 27.655.512 | |
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 305.810 | 2.512.960 | 13,86 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 611.620 | 2.207.150 | 38,33 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 1.595.530 | 1.595.530 | |||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Series A-1 Preferred Stock |
C - Conversion | -117.441 | 0 | -100,00 | ||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Convertible Subordinated Notes |
C - Conversion | |||||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | -141.825 | 0 | -100,00 | ||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -328.821 | 0 | -100,00 | ||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -1.393.000 | 0 | -100,00 | ||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 1.120.833 | 3.856.697 | 40,97 | 6,00 | 6.724.998 | 23.140.182 | |
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
C - Conversion | 158.174 | 2.735.864 | 6,14 | 6,00 | 949.044 | 16.415.184 | |
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
C - Conversion | 460.350 | 2.577.690 | 21,74 | ||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
C - Conversion | 1.950.200 | 2.117.340 | 1.166,81 | ||||
2014-06-02 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
C - Conversion | 164.417 | 167.140 | 6.038,08 | ||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-22 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
5.446 | ||||||||
2014-05-02 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 4.680 | 4.680 | |||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series C Warrants |
X - Other | -1.614 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | -9.359 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series B-1 Convertible Preferred Stock |
C - Conversion | -62.575 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series C Warrants |
X - Other | -98.368 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | -569.538 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series B-1 Convertible Preferred Stock |
C - Conversion | -850.520 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | -1.028.613 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | -1.927.986 | 0 | -100,00 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
X - Other | 357 | 72.291 | 0,50 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
C - Conversion | 9.359 | 71.934 | 14,96 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
C - Conversion | 62.575 | 62.575 | |||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 333.333 | 4.770.828 | 7,51 | 15,00 | 4.999.995 | 71.562.420 | |
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
X - Other | 21.837 | 4.437.495 | 0,49 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
C - Conversion | 569.538 | 4.415.658 | 14,81 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
C - Conversion | 850.520 | 3.846.120 | 28,39 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
C - Conversion | 1.028.613 | 2.995.600 | 52,29 | ||||
2014-02-20 |
|
4 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
C - Conversion | 1.927.986 | 1.966.987 | 4.943,43 | ||||
2014-02-11 | 3 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common stock, $0.001 par value |
87.362 | ||||||||
2014-02-11 | 3 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
57.721 | ||||||||
2014-02-11 | 3 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common stock, $0.001 par value |
87.362 | ||||||||
2014-02-11 | 3 | EGRX |
EAGLE PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
57.721 | ||||||||
2014-02-10 | 3 | PGSI |
Pegasi Energy Resources Corporation.
Common Stock, Par Value $0.001 |
11.392.948 | ||||||||
2014-02-10 | 3 | PGSI |
Pegasi Energy Resources Corporation.
Common Stock, Par Value $0.001 |
6.151.226 | ||||||||
2014-02-10 | 3 | PGSI |
Pegasi Energy Resources Corporation.
Common Stock, Par Value $0.001 |
11.392.948 | ||||||||
2014-02-10 | 3 | PGSI |
Pegasi Energy Resources Corporation.
Common Stock, Par Value $0.001 |
6.151.226 | ||||||||
2012-02-13 |
|
4 | NVDL |
NOVADEL PHARMA INC
Series A Warrants to Purchase Common Stock |
J - Other | 14.696.117 | 17.120.360 | 606,21 | ||||
2008-08-07 | 3 | AVNR |
AVANIR PHARMACEUTICALS
Class A Common Stock |
7.820.470 | ||||||||
2005-12-02 |
|
4/A | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -31.900 | 5.803.972 | -0,55 | 3,95 | -126.005 | 22.925.689 | |
2005-12-02 |
|
4/A | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -34.900 | 5.835.872 | -0,59 | 3,94 | -137.506 | 22.993.336 | |
2005-12-02 |
|
4/A | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -31.700 | 5.870.772 | -0,54 | 3,93 | -124.581 | 23.072.134 | |
2005-12-02 |
|
4/A | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -92.800 | 5.902.472 | -1,55 | 3,92 | -363.776 | 23.137.690 | |
2005-12-02 |
|
4/A | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -32.000 | 5.995.272 | -0,53 | 3,91 | -125.120 | 23.441.514 | |
2005-12-02 |
|
4/A | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -134.700 | 6.027.272 | -2,19 | 3,90 | -525.330 | 23.506.361 | |
2005-12-01 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -31.900 | 5.803.972 | -0,55 | 3,95 | -126.005 | 22.925.689 | |
2005-12-01 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -34.900 | 5.835.872 | -0,59 | 3,94 | -137.506 | 22.993.336 | |
2005-12-01 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -31.700 | 5.870.772 | -0,54 | 3,93 | -124.581 | 23.072.134 | |
2005-12-01 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -92.800 | 5.902.472 | -1,55 | 3,92 | -363.776 | 23.137.690 | |
2005-12-01 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -32.000 | 5.995.272 | -0,53 | 3,91 | -125.120 | 23.441.514 | |
2005-12-01 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock |
S - Sale | -134.700 | 6.027.272 | -2,19 | 3,90 | -525.330 | 23.506.361 | |
2005-02-04 | 3 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
3.301.565 | ||||||||
2005-02-04 | 3 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
138.640 | ||||||||
2005-02-04 | 3 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
3.440.205 |